A Study of Rapamycin Combined With Intravesical BCG in Patients With Non-muscle Invasive Bladder Cancer
Status:
Completed
Trial end date:
2021-03-02
Target enrollment:
Participant gender:
Summary
This study is looking at the effects of Sirolimus (Rapamycin) on BCG-specific immunity during
treatment of non-muscle invasive bladder cancer (NMIBC) with maintenance BCG.
Phase:
Early Phase 1
Details
Lead Sponsor:
The University of Texas Health Science Center at San Antonio